- Vallet N, Salmona M, Malet-Villemagne J, Bredel M, Bondeelle L, Tournier S, Mercier-Delarue S, Cassonnet S, Ingram B, Peffault de Latour R, Bergeron A, Socié G, Le Goff J*, Lepage P*, Michonneau D*. Circulating T cell profiles associate with enterotype signatures underlying hematological malignancy relapses. Cell Host Microbe. 2023 Aug 9;31(8):1386-1403.e6. doi: 10.1016/j.chom.2023.06.009.
- Ilhan ZE, Brochard V, Lapaque N, Auvin S, Lepage P. Exposure to anti-seizure medications impact growth of gut bacterial species and subsequent host response. Neurobiol Dis. 2022 Jun 1;167:105664. doi: 10.1016/j.nbd.2022.105664.
- Rozé JC, Ancel PY, Marchand-Martin L, Rousseau C, Montassier E, Monot C, Le Roux K, Butin M, Resche-Rigon M, Aires J, Neu J, Lepage P*, Butel MJ*; EPIFLORE Study Group. Assessment of Neonatal Intensive Care Unit Practices and Preterm Newborn Gut Microbiota and 2-Year Neurodevelopmental Outcomes. JAMA Netw Open. 2020 Sep 1;3(9):e2018119. doi: 10.1001/jamanetworkopen.2020.18119.
- Chemouny JM, Gleeson PJ, Abbad L, Lauriero G, Boedec E, Le Roux K, Monot C, Bredel M, Bex-Coudrat J, Sannier A, Daugas E, Vrtovsnik F, Gesualdo L, Leclerc M, Berthelot L, Ben Mkaddem S, Lepage P, Monteiro RC. Modulation of the microbiota by oral antibiotics treats immunoglobulin A nephropathy in humanized mice. Nephrol Dial Transplant. 2019 Jul 1;34(7):1135-1144. doi: 10.1093/ndt/gfy323.
- Just S, Mondot S, Ecker J, Wegner K, Rath E, Gau L, Streidl T, Hery-Arnaud G, Schmidt S, Lesker TR, Bieth V, Dunkel A, Strowig T, Hofmann T, Haller D, Liebisch G, Gérard P, Rohn S, Lepage P*, Clavel T*. The gut microbiota drives the impact of bile acids and fat source in diet on mouse metabolism. Microbiome. 2018 Aug 2;6(1):134. doi: 10.1186/s40168-018-0510-8.
- Chaput N*, Lepage P*, Coutzac C, Soularue E, Le Roux K, Monot C, Boselli L, Routier E, Cassard L, Collins M, Vaysse T, Marthey L, Eggermont A, Asvatourian V, Lanoy E, Mateus C, Robert C, Carbonnel F. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2017 Jun 1;28(6):1368-1379. doi: 10.1093/annonc/mdx108.
- Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CP, Poirier-Colame V, Roux A, Becharef S, Formenti S, Golden E, Cording S, Eberl G, Schlitzer A, Ginhoux F, Mani S, Yamazaki T, Jacquelot N, Enot DP, Bérard M, Nigou J, Opolon P, Eggermont A, Woerther PL, Chachaty E, Chaput N, Robert C, Mateus C, Kroemer G, Raoult D, Boneca IG, Carbonnel F, Chamaillard M, Zitvogel L. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015 Nov 27;350(6264):1079-84. doi: 10.1126/science.aad1329.
- Ilhan ZE, Łaniewski P, Thomas N, Roe DJ, Chase DM, Herbst-Kralovetz MM. Deciphering the complex interplay between microbiota, HPV, inflammation and cancer through cervicovaginal metabolic profiling. EBioMedicine. 2019 Jun;44:675-690. doi: 10.1016/j.ebiom.2019.04.028.
Tous les articles de l’équipe sont disponibles dans la collection PHYLHOM-MICALIS sur HAL.
PhylHom coordonne 4 projets financés par :
Les projets collaboratifs actuels sont également financés par :
- Agence Nationale de la Recherche ANR (2 projets)
- Programme Hospitalier de Recherche Clinique PHRC (3 projets)
- Région Ile-De-France DIM (ITAC)
- Grands Défis (GD Ferments du Futur)
- Villa Albertine pour le partenariat transatlantique de recherche
Principales sources de financement passées : ANR (2019, 2018, 2015, 2014, 2013), ANR-DFG (2013), PHRC (2014, 2014), INCa (2016, 2012), IA-RHU (2017), INRAE-Metaprogram (2012).